Progress of antibody-drug conjugates in the treatment of gastric cancer and adenocarcinoma of esophageal-gastric junction
10.3760/cma.j.cn115355-20240116-00038
- VernacularTitle:抗体-药物偶联物在治疗胃癌和胃食管结合部腺癌中的研究进展
- Author:
Qian XU
1
;
Dapeng LI
Author Information
1. 苏州大学附属第一医院肿瘤科，苏州 215006
- Keywords:
Stomach neoplasms;
Esophagogastric junction;
Receptor, erbB-2;
Antibodies, monoclonal;
Molecular targeted therapy
- From:
Cancer Research and Clinic
2024;36(7):549-553
- CountryChina
- Language:Chinese
-
Abstract:
Gastric cancer is a malignant tumor originating from the epithelium of the gastric mucosa and it is one of the most common malignant tumors of the digestive tract. Patients with gastric cancer have high incidence, metastasis rate and mortality rate. Despite various treatments such as surgery, chemotherapy and immunotherapy, some patients still show recurrence, metastasis and poor prognosis due to its high heterogeneity, high recurrence rate and metastasis rate. Antibody-drug conjugates, a novel class of highly efficient anti-tumor drugs composed of monoclonal antibodies and small molecule cytotoxic payloads linked by a connector, provide a new treatment method for the treatment of gastric cancer due to the high targeting specificity and potent cytotoxic effects of small molecule chemotherapy drugs. Currently, they are being evaluated in multiple clinical trials targeting different sites. This article mainly reviews the latest research progress of antibody-drug conjugates in gastric cancer and adenocarcinoma of esophageal-gastric junction, as well as the challenges in the future development.
